NCT01253369View on ClinicalTrials.gov

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2014

Conditions
Small Cell Lung CancerLung CancerSCLC
Interventions
DRUG

Pazopanib

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT01253369 - Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter